Squamoproliferative lesions arising in the setting of BRAF inhibition

American Journal of Dermatopathology

Volumn 34, Issue 8, 2012, Pages 822-826

  Harvey, Nathan T ^a   Millward, Michael ^b,c   Wood, Benjamin A ^a,d  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BRAF inhibitors; Keratoacanthoma; Vemurafenib; Verrucous keratosis

Indexed keywords

B RAF KINASE; DABRAFENIB; SORAFENIB; VEMURAFENIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; MALE; PRIORITY JOURNAL; SKIN DISEASE; SQUAMOPROLIFERATIVE LESION; SQUAMOUS CELL CARCINOMA; VERRUCA VULGARIS; VERRUCOUS KERATOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KERATOACANTHOMA; KERATOSIS; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN DISEASES; SKIN NEOPLASMS;

EID: 84870052974     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182604873     Document Type: Article

References (17)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417: 949-954.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364: 2507-2516.
4. Ernstoff MS. Been there, not done that-melanoma in the age of molecular therapy. N Engl J Med. 2011;364: 2547-2548.
5. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009; 27:e59-e61.
6. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7: 20-23.
7. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23: 177-182.
8. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467: 596-599.
9. Weedon D. Weedon's Skin Pathology. 3rd ed. London, UK: Churchill Livingstone Elsevier; 2010.
10. Elston DM, Ferringer T, ed. Dermatopathology. New York, NY: Saunders Elsevier; 2009.
11. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116: 855-867.
12. Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010; 107: 14903-14908.
13. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464: 431-435.
14. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140: 209-221.
15. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464: 427-430.
16. Leechanachai P, Banks L, Moreau F, et al. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factormediated signal transduction to the nucleus. Oncogene. 1992;7: 19-25.
17. Oberholzer PA, Kee D, Dziunycz P, et al. RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. J Clin Oncol. 2011;30: 316-321